Download PDF
Semin Thromb Hemost 2002; 28(2): 111-132
DOI: 10.1055/s-2002-27814
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications

Jan J. Michiels1 4 , Ann van de Velde1 , Huub H.D.M. van Vliet3 , Marc van der Planken2 , Wilfried Schroyens1 , Zwi Berneman1
  • 1Department of Hematology, University Hospital Antwerp, Belgiu
  • 2Department of Clinical Pathology, University Hospital Antwerp, Belgium
  • 3Hemostasis and Thrombosis Laboratory, University Hospital Rotterdam
  • 4Goodheart Institute, Hematology Hemostasis Thrombosis Science Center, Rotterdam, The Netherlands
Further Information

Publication History

Publication Date:
03 May 2002 (online)

    Permissions and Reprints

ABSTRACT

In the present study, we prospectively evaluated the contribution of the von Willebrand factor collagen-binding activity (vWF:CBA) assay, vWF multimeric analysis, and the response to intravenous desmopressin (DDAVP) to correctly diagnose and classify congenital von Willebrand disease (CvWD) in 24 probands with mild to moderate type 1 vWD, 6 probands with severe CvWD type 1, and 12 probands with type 2 CvWD. CvWD type 1 of mild to moderate severity is featured by proportionally decreased levels of vWF antigen (vWF:Ag), vWF ristocetin cofactor activity (vWF:RCof), and vWF:CBA between 0.20 and 0.60 u/mL and a normal response to DDAVP of factor (F) VIIIc and all vWF parameters. Severe type 1 CvWD with vWF parameters below 0.10 or 0.20 u/mL is associated with a decreased response to DDAVP of all vWF parameters, indicating a defective synthesis or secretion vWF by endothelial cells, or both. CvWD 2M may present as severe type 1 CvWD, as type 1 ``platelet-discordant'' CvWD, or with the combination of a discrepant vWF:RCof/Ag ratio and the presence of all vWF multimers. Ristocetin-induced platelet aggregation (RIPA) is normal in type 1 CvWD. CvWD 2M is typically featured by decreased RIPA, normal or near normal vWF multimers, and no or only a poor response to DDAVP of vWF:RCof as compared with a fairly good response to DDAVP of vWF:Ag and vWF:CBA. CvWD Vicenza is characterized by unusually large vWF multimers and very low levels of FVIIIc, vWF:Ag, and vWF:RCof. CvWD Vicenza differs from CvWD 2M because the vWF:RCof/Ag ratios are completely normal before and after DDAVP; the response to DDAVP is equally good for FVIIIc, vWF:Ag, vWF:RCof, and vWF:CBA and is followed by very short half-life times for FVIIIc and all vWF parameters. Pertinent findings in type 2A and 2B CvWD included prolonged Ivy bleeding time (BT), low vWF:RCof/Ag and vWF:CBA ratios, absence of the high vWF multimers, and, depending on the severity of the absence of intermediate vWF multimers, pronounced increase of low vWF multimers and vWF degradation products because of increased proteolysis of the high and intermediate vWF multimers. RIPA is normal in CvWD 2A and increased in CvWD 2B. The response to DDAVP in CvWD 2A is normal for FVIIIc and vWF:Ag but is transient with partial correction and short half-life times of vWF:CBA and vWF:RCof. DDAVP does not correct BT and multimeric patterns in CvWD type 2B, despite significant increase of vWF parameters. CvWD types 2C, 2D, and 2E are featured by very low functional vWF parameters, the presence of typically abnormal vWF multimers, a very poor response of vWF:CBA, a decreased response of vWF:RCof, and a fairly good response of vWF:Ag to DDAVP with no correction of prolonged Ivy BT and no correction of the vWF multimeric pattern as the consequence of a multimerization or dimerization defect of the vWF molecules. CvWD type 2N usually presents with much lower levels for FVIIIc as compared with vWF, normal Ivy BT, and normal vWF multimeric pattern. The response to DDAVP is normal for all vWF parameters but is decreased for FVIIIc with shortened half-life times.

KEYWORDS

von Willebrand factor - von Willebrand disease - ristocetin cofactor activity - von Willebrand factor collagen-binding activity - von Willebrand factor multimers - bleeding time - DDAVP

REFERENCES

  • 1 Nichols W C, Ginsberg D. Von Willebrand disease.  Medicine . 1997;  76 1-20
    CrossrefPubMedGoogle Scholar
  • 2 Ruggeri Z M. Structure of the von Willebrand factor and its function in platelet adhesion and thrombus formation.  Baillieres Clin Haematol . 2001;  14 251-279
    PubMedGoogle Scholar
  • 3 Sadler J E. A revised classification of von Willebrand disease.  Thromb Haemost . 1994;  71 520-525
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Sadler J E, Mannucci P M, Berntorp E. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost . 2000;  84 160-174
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Ivy A C, Nelson D, Bucher G. The standardization of certain factors in the cutaneous ``venostasis'' bleeding time technique.  J Lab Clin Med . 1941;  26 1812-1815
    PubMedGoogle Scholar
  • 6 Cejka J. Enzyme immunoassay for factor VIII-related antigen.  Clin Chem . 1984;  28 1356-1358
    PubMedGoogle Scholar
  • 7 Macfarlane D F, Stibbe J, Kirby E P. A method for assaying von Willebrand factor (ristocetin cofactor).  Thrombosis et Diathesis Haemorrhagica . 1975;  34 306-308
    PubMedGoogle Scholar
  • 8 Brown J E, Bosak J O. An ELISA test for the binding of von Willebrand factor antigen to collagen.  Thromb Res . 1986;  43 303-311
    CrossrefPubMedGoogle Scholar
  • 9 Brosstad F, Kjonniksen I, Ronning B, Stromorken H. Visualisation of von Willebrand factor multimers by enzyme-conjugated secondary antibodies.  Thromb Haemost . 1986;  55 276-278
    PubMedGoogle Scholar
  • 10 Eikenboom J CJ, Reitsma P H, Peerlinck K JM, Briët E. Recessive inheritance of von Willebrand's disease.  Lancet . 1993;  341 982-986
    CrossrefPubMedGoogle Scholar
  • 11 Schneppenheim R, Budde U, Ruggeri Z M. A molecular approach to the classification of von Willebrand Disease.  Baillieres Clin Haematol . 2001;  14 281-298
    PubMedGoogle Scholar
  • 12 Budde U, Drewke E, Mainush K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease.  Semin Thromb Hemost . 2001;  28 173-189
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Mannucci P M, Lombardi R, Bader R. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with abnormal von Willebrand factor.  Blood . 1985;  66 796-802
    PubMedGoogle Scholar
  • 14 Cattaneo M, Federici A B, Lecchi A. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.  Thromb Haemost . 1999;  82 35-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Federici A B, Canciani M T, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease.  Thromb Haemost . 2000;  84 1127-1128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Favaloro E J, Dean M, Grispo L, Exner T, Koutts J. Von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.  Am J Hematol . 1994;  45 205-211
    CrossrefPubMedGoogle Scholar
  • 17 Kempfer A C, Silaf M R, Farias C E. Binding of von Willebrand factor to collagen by flow cytometry.  Am J Clin Pathol . 1999;  111 418-423
    CrossrefPubMedGoogle Scholar
  • 18 Favaloro E J, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorders (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.  Haemophilia . 2001;  7 180-189
    CrossrefPubMedGoogle Scholar
  • 19 Casonato A, Pontara E, Bertomorop A. VWF:CBA in the diagnosis of VWD: an alternative to Rcof?.  Br J Haematol . 2001;  112 578-583
    CrossrefPubMedGoogle Scholar
  • 20 Federici A B, De Groot G Ph, Moia M. Type 1 von Willebrand disease, subtype ``platelet low'': decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells.  Br J Haematol . 1993;  83 88-93
    CrossrefPubMedGoogle Scholar
  • 21 Mancusco D J, Kroner P hA, Christopherson P M. Type 2M:Milwaukee-1 von Willebrand disease an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.  Blood . 1996;  88 2559-2568
    PubMedGoogle Scholar
  • 22 Hillery C A, Mabcusco D J, Sadler J E. Type 2M von Willebrand disease: F606I and I662F mutations in the GPIb binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.  Blood . 1998;  91 1572-1581
    PubMedGoogle Scholar
  • 23 Hilbert L, Jenkins P V, Gaucher G. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.  Thromb Haemost . 2000;  84 188-194
    PubMedGoogle Scholar
  • 24 Nitu-Whalley I C, Ridell A, Lee C. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling.  Thromb Haemost . 2000;  84 998-1004
    PubMedGoogle Scholar
  • 25 Lethagen S, Frick K, Isaksson C, Kristoffersson A-C, Holmberg L. Revised classification and treatment of von Willebrand disease.  Thromb Haemost . 1998;  80 199-200
    PubMedGoogle Scholar
  • 26 Hoyer L W, Rizza C R, Tuddenham G D. Von Willebrand factor multimer patterns in von Willebrand's disease.  Br J Haematol . 1983;  55 493-507
    PubMedGoogle Scholar
  • 27 Nishikubo T, Christophe O, Lavergne J-M. Abnormal proteolytic processing of von Willebrand factor Arg611Cys and Arg611His.  Thromb Haemost . 1997;  77 174-182
    PubMedGoogle Scholar
  • 28 Zang Z, Linstedt M, Blombäck M, Anvret M. Effects of the mutant von Willebrand factor gene in von Willebrand disease.  Hum Genet . 1995;  96 388-394
    PubMedGoogle Scholar
  • 29 Meyer D, Fressinaud E, Gaucher C. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene.  Thromb Haemost . 1997;  78 451-456
    PubMedGoogle Scholar
  • 30 Ribba A S, Hilbert L, Lavergne J M. The Arg552Cys (R552C) mutation within the A1 loop of von Willebrand factor (vWF) induces abnormal folding with loss-of-function resulting in 2A-like phenotype of von Willebrand disease. Study of ten patients and of mutated recombinant vWF.  Blood . 2001;  97 952-959
    CrossrefPubMedGoogle Scholar
  • 31 Mannucci P M, Lombardi R, Castaman G. Von Willebrand disease ``Vicenza'' with larger-than-normal (supranormal) von Willebrand factor multimers.  Blood . 1988;  71 65-70
    PubMedGoogle Scholar
  • 32 Fressinaud E, Veyradier A, Truchaud F. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.  Blood . 1998;  91 1325-1331
    CrossrefPubMedGoogle Scholar
  • 33 Favaloro E J. Von Willebrand factor collagen-binding (activity) assay (vWF:CBA) in the diagnosis of von Willebrand disease (vWD): a 15-year journey.  Semin Thromb Hemost . 2002;  28 191-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Favaloro E J. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations.  Haemophilia . 2001;  7 170-179
    CrossrefPubMedGoogle Scholar
  • 35 Mazurier C, Goudmand J, Helbert L. Type2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.  Ballieres Clin Haematol . 2001;  14 337-347
    PubMedGoogle Scholar
  • 36 Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N (Normandy) von Willebrand disease.  Br J Haematol . 1994;  88 849-854
    PubMedGoogle Scholar
      >